Efficacy and safety of patiromer for hyperkalemia: a randomized, placebo-controlled phase 3 study
Patiromer can improve hyperkalemia by lowering sK-level and can suppress the recurrence of hyperkalemia with continued administration, and is safe and easy-to-use for a wide range of patients.
Authors
- Naoki Kashihara (ORCID: https://orcid.org/0000-0002-9487-984X)
- Masaru Matsui (ORCID: https://orcid.org/0000-0001-9646-6363)
- Yukio Tomioka
- Takayuki Ishii (ORCID: https://orcid.org/0000-0002-1494-2141)
- Hirokazu Okada (ORCID: https://orcid.org/0000-0002-1839-9078)
- Tamio Iwamoto (ORCID: https://orcid.org/0000-0002-0265-4791)
- Masashi Yasutomi
- Ryo Takezawa
- Yusuke Suzuki (ORCID: https://orcid.org/0009-0007-4384-005X)
Institutions
- Kawasaki Medical School (JP)
- Juntendo University (JP)
- Zeria Pharmaceutical (Japan) (JP)
- Sunagawa City Medical Center (JP)
- Saiseikai Ibaraki Hospital (JP)
- Nara Prefecture General Medical Center (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Clinical and Experimental Nephrology
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1007/s10157-025-02637-4
- Citations
- 2
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Baxter International
- Gilead Sciences
- Takeda Pharmaceutical Company
- Kyowa Kirin Pharmaceutical Development
- Torii Pharmaceutical
- Boehringer Ingelheim Japan
- Daiichi-Sankyo
- Astellas Pharma
- Otsuka Pharmaceutical
- Toray Industries
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical
- Chugai Pharmaceutical
- Bayer Yakuhin